Latest

5 stories

Hide weekly roundups

Tuesday, September 22

Attovia registers Phase 2 trial of ATTO-1310 for chronic pruritus of unknown origin

Trial updateATTO-1310 Attovia Therapeutics Inc

Tuesday, September 15

Attovia registers Phase 1 trial of ATTO-1091 for ulcerative colitis

Trial updateATTO-1091 Attovia Therapeutics Inc

Wednesday, September 2

Quarterly updateATTO-1310 Attovia Therapeutics Inc

Attovia reports ATTO-1310 pruritus proof of concept, plans Phase 2 for 2027

Attovia said its Phase 1b trial produced early clinical proof of concept for ATTO-1310 in itch conditions, with full data due in the fourth quarter and two Phase 2 studies planned for the first half of 2027.

SEC filing

Wednesday, August 5

FinancingAttovia Therapeutics Inc

Attovia Therapeutics prices $289 million IPO ahead of Nasdaq debut

The clinical-stage biotech sold 17 million shares at $17 to fund its IL-31 and IL-13 pipeline, with trading set to begin under the ticker "ATTO."

SEC filing

Tuesday, July 14

FinancingAttovia Therapeutics Inc

Attovia Therapeutics files S-1 for IPO on Nasdaq under ticker ATTO

The clinical-stage biotech disclosed $255.8 million raised to date as it seeks public funding to advance three ATTOBODY pipeline candidates.

SEC filing